| Dr Algie Labrasca, DO | |
|
50 Waterford Pike, Brookville, PA 15825-2518 | |
| (814) 849-6591 | |
| (814) 849-9942 |
| Full Name | Dr Algie Labrasca |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 21 Years |
| Location | 50 Waterford Pike, Brookville, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194924084 | NPI | - | NPPES |
| 1025006630001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | OS015234 (Pennsylvania) | Secondary |
| 208200000X | Plastic Surgery | OS015234 (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Labrasca Plastic Surgery Llc | 1951531870 | 2 |
News Archive
Celtic Pharmaceutical Holdings L.P., the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also known as a fungal nail infection).
Drug discovery company SCYNEXIS, Inc. today presented data supporting an impressive resistance profile for SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection. In the study, SCYNEXIS demonstrated that the hepatitis C virus required multiple mutations across two separate proteins in order to establish resistance to SCY-635. The majority of HCV drugs on the market and in development require only one targeted viral mutation to establish resistance.
Jane Harrop, a 30 year old British woman was complaining of headaches for several days that made her feel "drunk". She was diagnosed to be suffering from migraine but died two days later from a viral infection of the brain.
ReSearch Pharmaceutical Services, Inc., a leading provider of integrated clinical development outsourcing solutions to the biopharmaceutical industry, announces its results for the three and six months ended June 30, 2010. These statements include unaudited comparative results for RPS for the three and six months ended June 30, 2009.
› Verified 8 days ago
| Entity Name | Labrasca Plastic Surgery Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487083663 PECOS PAC ID: 1951531870 Enrollment ID: O20140220000493 |
News Archive
Celtic Pharmaceutical Holdings L.P., the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also known as a fungal nail infection).
Drug discovery company SCYNEXIS, Inc. today presented data supporting an impressive resistance profile for SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection. In the study, SCYNEXIS demonstrated that the hepatitis C virus required multiple mutations across two separate proteins in order to establish resistance to SCY-635. The majority of HCV drugs on the market and in development require only one targeted viral mutation to establish resistance.
Jane Harrop, a 30 year old British woman was complaining of headaches for several days that made her feel "drunk". She was diagnosed to be suffering from migraine but died two days later from a viral infection of the brain.
ReSearch Pharmaceutical Services, Inc., a leading provider of integrated clinical development outsourcing solutions to the biopharmaceutical industry, announces its results for the three and six months ended June 30, 2010. These statements include unaudited comparative results for RPS for the three and six months ended June 30, 2009.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Algie Labrasca, DO 50 Waterford Pike, Brookville, PA 15825-2518 Ph: (814) 849-6591 | Dr Algie Labrasca, DO 50 Waterford Pike, Brookville, PA 15825-2518 Ph: (814) 849-6591 |
News Archive
Celtic Pharmaceutical Holdings L.P., the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also known as a fungal nail infection).
Drug discovery company SCYNEXIS, Inc. today presented data supporting an impressive resistance profile for SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection. In the study, SCYNEXIS demonstrated that the hepatitis C virus required multiple mutations across two separate proteins in order to establish resistance to SCY-635. The majority of HCV drugs on the market and in development require only one targeted viral mutation to establish resistance.
Jane Harrop, a 30 year old British woman was complaining of headaches for several days that made her feel "drunk". She was diagnosed to be suffering from migraine but died two days later from a viral infection of the brain.
ReSearch Pharmaceutical Services, Inc., a leading provider of integrated clinical development outsourcing solutions to the biopharmaceutical industry, announces its results for the three and six months ended June 30, 2010. These statements include unaudited comparative results for RPS for the three and six months ended June 30, 2009.
› Verified 8 days ago